Clinical trials: PD-1 Inhibitors
Breast Cancer
Window Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC)
The goal of this clinical trial is to study the safety, feasibility, histologic and immunological effects of Mitazalimab, a CD40 agonistic antibody, when administered either alone or in combination with PD-1 inhibition prior to…
- Trial name
- WINIT-BC (NCT07319195)
- Testing
- Intratumoral Mitazalimab, Intratumoral Nivolumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Jennifer Zhang
Hepatocellular Carcinoma (HCC), Bone Metastases
Denosumab Strategy for Liver Cancer With Bone Metastases
This study will evaluate whether starting denosumab early, together with a locked uniform PD-1-based systemic therapy, can reduce skeletal-related events and delay worsening bone pain compared with a delayed/rescue bone-modifying…
- Trial name
- NCT07537972
- Testing
- Denosumab, Sintilimab, Delayed/Rescue Bone-Modifying Strategy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tongji Hospital
Esophageal Carcinoma, Radiotherapy
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
The goal of this clinical trial is to learn if concurrent chemoradiotherapy followed by immunotherapy as maintenance therapy works to treat locally advanced esophageal squamous cell cancer in adults.
- Conditions
- Esophageal Carcinoma, Radiotherapy, Immunotherapy
- Trial name
- NCT06964568
- Testing
- PD-1 inhibitor, Unlimited radiotherapy, TP regimen
- Where
- China
- Volunteers
- 452 people
- Sponsor
- Fudan University
Non Small Cell Lung Cancer Recurrent
Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)
This is a phase II, single arm, open-label, single-center study to evaluate the efficacy and safety of Toripalimab combined with Chemotherapy and Antiangiogenic Agents in patients with Non-Small Cell Lung Cancer After Failure of…
- Trial name
- NCT05842018
- Testing
- Toripalimab, Anlotinib and Chemotherapy
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
This is a single-center, single-arm, phase II clinical trial designed to evaluate the efficacy and safety of becotatug vedotin combined with gemcitabine and a PD-1 inhibitor as second-line or later treatment for patients with…
- Trial name
- NCT07902713
- Testing
- Becotatug Vedotin (MRG003), Gemcitabine (1000 mg/m2), Camrelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Oropharyngeal Cancer
PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC
More and more studies have shown that the efficacy and prognosis of HPV （Human papillomavirus）-positive oropharyngeal cancer (OPC) patients are better than those of others.
- Trial name
- NCT06156891
- Testing
- Toxicities reduced treatment, Conventional treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Colorectal Cancer Liver Metastasis
A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM
The goal of this study is to evaluate the efficacy and safety of multi-mode ablation combined with systemic therapy including PD-1(programmed death receptor 1) inhibitor for colorectal cancer liver metastasis and furthermore to…
- Trial name
- NCT06590259
- Testing
- Multi-mode tumor treatment system, Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai 6th People's Hospital
Penile Cancer
EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer
This clinical study is a Phase II research trial focused on a new preoperative treatment for men with advanced penile squamous cell carcinoma (a type of penile cancer).
- Trial name
- MH-Penile-002 (NCT07518979)
- Testing
- Becotatug Vedotin, Pucotenlimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jiyan Liu
Nasopharyngeal Cancer Recurrent
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.
- Trial name
- TRANSPARENT (NCT06457503)
- Testing
- Toripalimab, Cisplatin, Gemcitabine
- Where
- 13 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Coherus Oncology, Inc.
UC (Urothelial Cancer)
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo as a treatment for recurrent or progressive metastatic urothelial carcinoma in patients who have failed a…
- Trial name
- NCT03374488
- Testing
- Pembrolizumab, Epacadostat
- Where
- 135 sites in United States, Australia and 16 more
- Volunteers
- 84 people
- Sponsor
- Incyte Corporation
Metastatic Melanoma, Liver Metastases
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to…
- Trial name
- NCT07281924
- Testing
- Nivolumab and Relatlimab, Melphalan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Wisconsin, Madison
Esophageal Neoplasms
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
The treatment efficacy for stage IVb esophageal cancer has been improved through chemotherapy combined with immunotherapy recently.
- Trial name
- NCT06086457
- Testing
- Radiation, TP or PF regimen depended on investigator's choice., PD-1 inhibitor
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Rectal Cancer, Neoadjuvant Therapies
Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)
The goal of this clinical trial is to evaluate whether a total neoadjuvant therapy (TNT) regimen combining long-course chemoradiotherapy, sequential chemotherapy, and PD-1 inhibitor can improve response rates, enhance…
- Conditions
- Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy
- Trial name
- NCT06923345
- Testing
- Reduced CTV, Conventional CTV
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Non Small Cell Lung Cancer
Lindera Obtusiloba for Non-small Cell Lung Cancer
This randomized, open labelled, non-treatment-controlled study evaluates the safety and efficacy of Lindera obtusiloba, a dietary food, on quality of life of non-small cell lung cancer patients who are receiving PD-1 or PD-L1…
- Trial name
- NCT04348149
- Testing
- Lindera obtusiloba extract
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Jun-Yong Choi
Nasopharyngeal Carcinoma
Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma
This study is to investigate the efficacy and safety of the induction chemotherapy + concurrent chemoradiotherapy（CCRT）combined with toripalimab and endostar treatment, in comparison with the induction chemotherapy + concurrent…
- Trial name
- NCT04447326
- Testing
- Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy, IC＋CCRT
- Volunteers
- 106 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
NSCLC (Non-small Cell Lung Cancer)
WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
This prospective Phase II study aims to evaluate the preliminary efficacy and safety of WAST cells combined with docetaxel as second-line therapy in patients with advanced NSCLC resistant to PD-1 inhibitors.
- Trial name
- NCT07330050
- Testing
- Whole Agonist-Stimulated T (WAST) cells injection, Docetaxel
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Oral Squamous Cell Carcinoma
Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy
This study aims to investigate the efficacy and safety of neoadjuvant Toripalimab combined with Nimotuzumab in primary limited stage oral squamous cell carcinoma prior to radical therapy.
- Trial name
- NCT05803915
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Cancer, PD-L1
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
To investigate the activating effect of local lesion low-dose radiotherapy (2Gy) on the tumor immune microenvironment, and the efficacy, safety, and feasibility of its combination with pembrolizumab and standard therapy in…
- Conditions
- Pancreatic Cancer, PD-L1, PD-1 Inhibitor, LDRT
- Trial name
- NCT07312422
- Testing
- Low-dose Radiotherapy, Pucotenlimab, AG regimen
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Zhejiang Provincial People's Hospital
Advanced Solid Tumors
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
The goal of this clinical trial is to assess the safety and tolerability of AT1019 when used in combination with SBRT and PD-1 inhibitor, and determine the maximum tolerated dose (MTD) of AT1019 in the combination therapy of SBRT…
- Trial name
- NCT07285395
- Testing
- AT1019
- Where
- China
- Volunteers
- 12 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Hepatocellular Carcinoma, Regorafenib
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
This is a single arm, nonrandomized, single center clinical study to investigate the safety and efficacy of regorafenib combined with PD-1 inhibitor therapy for second-line treatment of hepatocellular carcinoma
- Conditions
- Hepatocellular Carcinoma, Regorafenib, PD-1 Inhibitor
- Trial name
- NCT05048017
- Testing
- Regorafenib, PD-1 inhibitor
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital